Association between interleukin-22 genetic polymorphisms and bladder cancer risk

Zhao, Tao; Wu, Xiaohou; Liu, JiaJi

doi:10.6061/clinics/2015(10)05

Cited by 13 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, a total four polymorphisms in seven studies were included . Among the seven articles, three articles investigated the gastric cancer, one investigated bladder cancer, two investigated colon cancer, and one investigated the thyroid cancer . Table shows the characteristics of included studies and Table shows the genotype distribution of included studies.…”

Section: Resultsmentioning

confidence: 99%

“…Recently, more and more studies suggest that IL‐22 may contribute to the pathogenesis of cancer . There were many studies that focused on the relationship between IL‐22 polymorphisms and cancer risk, but the results are still controversial. Therefore, we performed a meta‐analysis to further determine an accurate relationship between IL‐22 polymorphisms polymorphism and cancer susceptibility.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Four polymorphisms in the IL‐22 gene and the risk of cancer: A meta‐analysis

Zhang

Zhao

et al. 2018

J Evidence Based Medicine

View full text Add to dashboard Cite

Objective: IL-22 plays an important role in cancer carcinogenesis. However, the association between IL-22 polymorphisms and cancer risk was inconclusive. The objective of the current study was to assess these associations by meta-analysis.Methods: PubMed, EMbase, CNKI, VIP, and Wanfang databases were searched up to 31 January 2018. The results were screened according to the inclusion and exclusion criteria. The associations between polymorphisms and cancer risk were estimated by meta-analysis. All analyses were performed using the Revman5.3 software. Results:A total of four polymorphisms (rs2227485, rs1179251, rs1179246, and rs1182844) in seven studies were included. The results of meta-analysis indicated that the rs1179251 polymorphism [OR = 1.46, 95% CI (1.17, 1.82), P = 0.0008 for GG+GC vs. CC] was associated with increased risk of cancer, while the rs2227485, rs1179246, and rs1182844 polymorphisms were not associated with cancer risk. Conclusions:The current meta-analysis suggests that IL-22 gene rs1179251 polymorphism may be a risk factor for cancer. K E Y W O R D Scancer, IL-22, meta-analysis, polymorphism

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Four polymorphisms in the IL‐22 gene and the risk of cancer: A meta‐analysis

Zhang

Zhao

et al. 2018

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…A recent study found an association of a SNP in the human IL22 locus with a two‐fold risk increase for bladder cancer. Interestingly and of clinical relevance, superficial bladder cancers, which are associated with a better prognosis, were not correlated with this SNP .…”

Section: Il‐22 and Cancermentioning

confidence: 89%

A catch‐22: Interleukin‐22 and cancer

2018

View full text Add to dashboard Cite

Barrier surfaces of multicellular organisms are in constant contact with the environment and infractions to the integrity of epithelial surfaces is likely a frequent event. Interestingly, components of the immune system, that can be activated by environmental compounds such as the microbiota or nutrients, are interspersed among epithelial cells or directly underlie the epithelium. It is now appreciated that immune cells continuously receive and integrate signals from the environment. Curiously, such continuous reception of stimulation does not normally trigger an inflammatory response but mediators produced by immune cells in response to such signals seem to rather promote barrier integrity and repair. The molecular mediators involved in this process are poorly understood. In recent years, the cytokine interleukin-22, produced mainly by group 3 innate lymphoid cells (ILCs), has been studied as a paradigm for how immune cells can control various aspects of epithelial cell function because expression of its receptor is restricted to non-hematopoietic cells. We will summarize here the diverse roles of IL-22 for the malignant transformation of epithelial cells, for tumor growth, wound healing and tissue repair. Furthermore, we will discuss IL-22 as a potential therapeutic target. Keywords:Aryl hydrocarbon receptor r Cancer r IL-22 r Innate lymphoid cells r RORγt IntroductionBarrier organs like the skin, the gut and lung mucosae are in constant contact with the environment. Their cellular components need to adapt to the continuous and ever changing presence of a large number of microbes (i.e., bacteria, fungi, viruses and parasites collectively referred to as the "microbiome") and their metabolites, including toxins. In addition, the epithelial barrier of the intestine is also subjected to food components, some of which are toxic by being poisonous, noxious or irritating. The skin barrier is exposed to UV irradiation, which is beneficial (e.g., conversion of Vitamin D) but can also be harmful (e.g., direct and Correspondence: Dr. Andreas Diefenbach e-mail: andreas.diefenbach@charite.de indirect DNA damage). Thus, barrier surfaces with the environment are sites where adaptive processes are initiated. Over millions of years of co-evolution of multicellular organisms with their habitat, adaptive signaling networks have been selected that are believed to shield the organism against such continuous threats and, thereby, shape their fitness. A well-studied example of such adaptive processes is microbiota-host relationships [1]. Through contact with microbial communities, epithelial function is being modified as to minimize damage to the barrier. For example, epithelial cells directly receive signals from the microbiota leading to the production of anti-bacterial proteins and to the protection of epithelial cells against TNF-triggered apoptosis [2][3][4]. * These authors contributed equally to this work.C 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 16Pedro Hernandez et al. Eur. J. Immunol. 2018. 48: ...

show abstract

“…For this review, 373 full-text articles were evaluated in depth, resulting in a final set of 112 articles for further summary (Figure 1). In total, 316 associations were extracted across all investigated outcomes as follows: age (N = 12 11-22 ), stage (N = 79 11,13,18,20,23-66 ), tumor size (N = 2 67,68 ), grade (N = 49 11,18,27,29,32,33,35…”

Section: Resultsmentioning

confidence: 99%

Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer

et al. 2019

View full text Add to dashboard Cite

Introduction:Many germline associations have been reported for urinary bladder cancer (UBC) outcomes and prognostic characteristics. It is unclear whether there are overlapping genetic patterns for various prognostic endpoints. We aimed to review contemporary literature on genetic associations with UBC prognostic outcomes and to identify potential overlap in reported genes.Methods:EMBASE, MEDLINE, and PubMed databases were queried for relevant articles in English language without date restrictions. The initial search identified 1346 articles. After exclusions, 112 studies have been summarized. Cumulatively, 316 single-nucleotide polymorphisms (SNPs) were reported across prognostic outcomes (recurrence, progression, death) and characteristics (tumor stage, grade, size, age, risk group). There were considerable differences between studied outcomes in the context of genetic associations. The most commonly reported SNPs were located in OGG1, TP53, and MDM2. For outcomes with the highest number of reported associations (ie, recurrence and death), functional enrichment annotation yields different terms, potentially indicating separate biological mechanisms.Conclusions:Our study suggests that all UBC prognostic outcomes may have different biological origins with limited overlap. Further validation of these observations is essential to target a phenotype that could best predict patient outcome and advance current management practices.

show abstract

Association between interleukin-22 genetic polymorphisms and bladder cancer risk

Cited by 13 publications

References 38 publications

Four polymorphisms in the IL‐22 gene and the risk of cancer: A meta‐analysis

Four polymorphisms in the IL‐22 gene and the risk of cancer: A meta‐analysis

A catch‐22: Interleukin‐22 and cancer

Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer

Contact Info

Product

Resources

About